(By Mani) Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), in addition to AstraZeneca and Astellas, had put in initial bids for Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR), according to a report on Bloomberg.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez, Cubist's President and COO, will present at the Bank of America Merrill Lynch 2013 Healthcare Conference on Wednesday, May 15, to discuss the company's business ...

Cubist Pharmaceuticals, Inc. ( CBST ) recently received encouraging news when the US Food and Drug Administration (FDA) granted the company's antibiotic candidate ceftolozane/tazobactam (CXA-201) a fast track status in Qualified Infectious Disease ...

... and the financial markets. Stocks recently featured in the blog include Exxon Mobil Corporation (NYSE: XOM), Statoil ASA (NYSE: STO), Chevron Corporation (NYSE: CVX), Braskem S.A.

NEW YORK (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told ...

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted ...

Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced results for the first quarter ended March 31, 2013. The Company will host a conference call and webcast today at 5:00 p.m.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Cubist Pharmaceuticals (NASDAQ: CBST) traded up 0.73% on Monday, hitting $46.63. Cubist Pharmaceuticals has a 52-week low of $36.73 and a 52-week high of $49.86.